December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Rahul Banerjee: ARROW2 was here all this time and just got published in Blood Advances
Jul 20, 2024, 21:30

Rahul Banerjee: ARROW2 was here all this time and just got published in Blood Advances

Rahul Banerjee, Assistant Professor at UW Medicine, shared a post by, Robert Z. Orlowski, on X, adding:

ARROW2 was here all this time and just got published in Blood Advances! KRd with K56-1x vs K27-2x in RRMM MMsm.

– No change in PFS. Non-non-inferior ORR likely artifactual.
9% of patients found K27-2x “inconvenient” vs 3% K56-1x

Nice commentary about time toxicity by authors.”

Rahul Banerjee

Quoting Robert Z. Orlowski’s post:

“Myeloma Paper of the Day: Once-weekly KRd56 appears similar to twice-weekly KRd27 for patients with relapsed/refractory myeloma, with ORR 82.5% vs. 86.3%, comparable PFS, and similar safety profiles while enhancing convenience.”
Rahul Banerjee

A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma published in PubMed

Autors: Meletios-Athanasios A Dimopoulos,  Daniel Coriu, Sosana Delimpasi, Ivan Spicka, Terry E Upchurch , Belle Fang  Rakhshandra Talpur, Edward Anthony Faber Jr, Meral Beksac, Xavier Leleu

Rahul Banerjee

Source: Rahul Banerjee/X and Robert Z. Orlowski/X

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.